{"name":"Selecta Biosciences, Inc.","slug":"selecta-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":900000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"KRYSTEXXA®","genericName":"KRYSTEXXA®","slug":"krystexxa","revenue":900000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":900000000,"percentOfTotal":100,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"KRYSTEXXA®","genericName":"KRYSTEXXA®","slug":"krystexxa","indication":"Gout","status":"marketed","revenue":900000000},{"name":"SEL-037","genericName":"SEL-037","slug":"sel-037","indication":"Other","status":"phase_2"},{"name":"SEL-068","genericName":"SEL-068","slug":"sel-068","indication":"Other","status":"phase_1"},{"name":"SEL-212","genericName":"SEL-212","slug":"sel-212","indication":"Other","status":"phase_2"},{"name":"SELA-070","genericName":"SELA-070","slug":"sela-070","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"KRYSTEXXA®","genericName":"KRYSTEXXA®","slug":"krystexxa","phase":"marketed","mechanism":"Krystexxa works by targeting a specific biological pathway to treat a particular condition.","indications":["Gout"],"catalyst":""},{"name":"SEL-037","genericName":"SEL-037","slug":"sel-037","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SEL-068","genericName":"SEL-068","slug":"sel-068","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"SEL-212","genericName":"SEL-212","slug":"sel-212","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SELA-070","genericName":"SELA-070","slug":"sela-070","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5vWHhveFE0WEtXa1lucFR4YTEtYmJxQ1Jqc0lQRk1RWktSZEZ0eWdSUDFxSkZMcnVVS3gzUkpXQkU4cjRzWXhyTk9FZ3VtM0FFd2lNUFAtTkxBN2R4WFRIZHVmOEdFMzQ?oc=5","date":"2026-01-08","type":"pipeline","source":"Market.us","summary":"Intravenous Pegloticase Market Size, Share | CAGR of 13.8% - Market.us","headline":"Intravenous Pegloticase Market Size, Share | CAGR of 13.8%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZGdsbXducVlCVF92ZzFNN1p6TGZ3NVFPcElGZlJ5cFYxX2tkQVllYkVXREJYYXFjbXNXWmpaNEVoN3cyWk9yVWpDMll0SVB2ZWdkMXd4aGNTTlNiSUZXQVJSZmRnM1EzVWJYVjM4NUNJQk5nSUw1X05XYmQ0MHFWVG9qcUdPRUo4d3FuWUdUNnFXWDVrLWx2X3FlNmE1dUVYZFlXR1JyZWhYR2s?oc=5","date":"2025-10-30","type":"pipeline","source":"citybiz","summary":"Cartesian Therapeutics Appoints Carsten Brunn, Ph.D., as Board Chairman - citybiz","headline":"Cartesian Therapeutics Appoints Carsten Brunn, Ph.D., as Board Chairman","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQTHpBWUtvejNfU2R3SHlwTWg3Rlc3cWROV0VvWlZUZ0FGazlsb0EyN2x1bFdlY0tTR2VRTk9FNHdzbWVPc2ZxVkZXaGN5dzA1bzBNOVBoUU82VGloOGZWWjlJU19sSE5IaHZvTThvUzZ4WHRHWEFoNVg1UUF0ZkVPWmhtTzJMa0RPc3VmeHpwZzU?oc=5","date":"2025-10-06","type":"pipeline","source":"citybiz","summary":"Traws Pharma Appoints John Leaman, MD, as Director - citybiz","headline":"Traws Pharma Appoints John Leaman, MD, as Director","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPNEx3eVdsSzFHVi1MSUxRenZ3TnlNbHBoSVhmVFBEYnJ3V3FIX1d5TlFFNnRqSnJWZTUxc1A1V3hyQnFIYUxfcXRxMHQ1b2x4bHpNWVRGTjNwci1SQ2FLZlVpQUowdHptTkVIQnpqdTNVWk95ck45aUdfRlBYdUo1d1ozQWxEajB5RGxoTWxnNkl5Y0VGZlBYYXMzeERSR1JVZ1B3dkVOREk2TXVNWWxMTFc4RW9iWkNwVWVIYWVrY0VCX2htU3NreHFGS3NvVFRBTk52TnZQTFFYVTlyYW1kaHRteWIyQTl1ZEpMc24yRkstUktTdUg5YzVXdFlVeldVMXFMY1NOZ1o?oc=5","date":"2025-09-16","type":"trial","source":"GlobeNewswire","summary":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight - GlobeNewswire","headline":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQbUl5eWJ0Tmh3aXdXRkgzUWNwcy03N0lITnVaaFNtVy0tbHVCM3VXTU85cFI2bW5iSmp1d2g0WG5OcXk1elBHUDNNcEw3T2lscThfN0NHM1FFY25YTmMzQ0N6ZldSLVBnNThlWkVITFViaHVtZUZWSWdjS2JDdUp2NGJDcmhfajhOOTJwZFluZ1E0QnhkdHc?oc=5","date":"2024-03-15","type":"deal","source":"BioSpace","summary":"Astellas Backs Out of Potential $340M Licensing Deal with Cartesian - BioSpace","headline":"Astellas Backs Out of Potential $340M Licensing Deal with Cartesian","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOeUlRbEVSMmxXZzI2NFJWLThYRzl6SUhiTzJwTVB5QzN6amdWYWZIQ0t0aTJCTlFEVUJPQlJFRVlSWDJsX0pTbTQxbmh2ZEJXQ0pOWU9ZM0l4QjRneHFac0xMcGpwQ0ZJQVowbUZKQ3V4cmN4bUprVFhKRFJ1clp3cllHak16cjF0NmFzZ1pvUkxlSktOSnBMMjROd3pmZ1U1R1YxVFBySmhDdVdj?oc=5","date":"2024-03-05","type":"deal","source":"The Business Journals","summary":"Biotech moving HQ outside of Montgomery County following merger - The Business Journals","headline":"Biotech moving HQ outside of Montgomery County following merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNWXFJenBiUGVqU1Q2UE5GbGFRWmpJd2hidk5sYmwwUjR6US1GZ1dCak1nUGpTcEVYUVNwVmx1d21UZ0gzbXRPWFl2Yy1OVXJkX21VRS10b2k5UnhGOXAyQlpDczBpaGtIZ2gyUmZfSlhVV2dVS0pTQWl4eEFrX3J5R0dMdENDOXVnYjBnUWQwVHBCTzNFMl9jVDFhWk9qSWJvQlF1am5ya0pvMGQyX0lsUDQ3dUpWNDJGYkJxdHppOTZiVmkt?oc=5","date":"2023-11-13","type":"deal","source":"fiercebiotech.com","summary":"Selecta fuses with Cartesian in reverse merger, bolstering finances for autoimmune cell therapy goals - fiercebiotech.com","headline":"Selecta fuses with Cartesian in reverse merger, bolstering finances for autoimmune cell therapy goals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQQjhja2xVWm5pa0lxMGVtRTc1ZWczV2pmLWxDZ2ZGRkg2NVRyV1VZU05PbFk2WndmNkhRVkNDMW5sVU1fNnFlRFJKR3FOY3dUWm03U3NReTh5NExIc0RGLTNnd2pyMEcwYVRkY21NQ0VlbXViRlZNWm5pLUFtS3dSNEptRmxVVXVRNUdaNHpzUmNxalAxb3FCS0poaVNKZmRfWmlDR0ktU0lqaG5vc1dCVGF6MXNXUEJ2c2tMS0IyR0tWVzFVMzNpX1JkOXJiYXVMbUE?oc=5","date":"2023-11-13","type":"deal","source":"GlobeNewswire","summary":"Selecta Biosciences Announces Merger with Cartesian Therapeutics - GlobeNewswire","headline":"Selecta Biosciences Announces Merger with Cartesian Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPWTZEXzNaT0FVTURtcTZWUk11VzIzcnhwM2wxbmNaVDJQQ3FpVHlqdXVKSkJyS2U4Vnc1eEZDVVgtNUlOQXlxMFBjeDhzLTM2T0JQaWRkOXRuMlJOUExpSlBZWTJLSE55Tlg4cDBiSHZmRTEwMmkzNElQcFZvaDlocDdUaFdJcVc2eG9fOEYwNTBJQ0ZramNBZ0VwTWprVkxGSUJvTVNn?oc=5","date":"2023-08-17","type":"pipeline","source":"fiercebiotech.com","summary":"Selecta narrows focus to gout drug, freezing rest of pipeline - fiercebiotech.com","headline":"Selecta narrows focus to gout drug, freezing rest of pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxOdU5iTTd5Qm5NUzJlZnQ3TmtranpkSllvWkNsQTFsamhUakJkMlZNZl94S1ZsY041dGFKUF9aMk9XQmtWdFZHa3FXTkJHcUV0RWNVSDh6dDRoZm5wVTY5TDlsV0lXeFdXM2lVUTJKRzhvSkozWTllTURydzA1LUFQSDFDX1pkck84Rk9DdUwzTlBUam8yQTNWQ0IzZ3NPd21PSV8yOWNIVE5ubkV2d0xialp1ZGtJT05uV0liLXJhcnVON0tkRDRwSFF1NmliX0tkd0tkVzFMSUpuc3R4c0FtQTc3Mm9DcDVZSUJjMU1QM2hvcGZ5R1lsUw?oc=5","date":"2023-01-09","type":"pipeline","source":"prnewswire.com","summary":"Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease - prnewswire.com","headline":"Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNVV83Q1lIRWxuSm04aVpPTU1yclhJem5qcjRTd01abkJ4ZHJqVUFWWXJzNVZvQ2tIajZKVFpoM0F1eVE1RE1UTnlYUUhvTk5rbTZvbUZ6T0RCZm5LelFBTjhJMGR3eExTNUNDNzlGUTNLZEVXZnpUdTBXelBvWlE4NnBLN3pGazJ0RTFMVGM1dGx3bTdDeTg4eEtvMThWVC02N3N3dkZvV3RyU0huQnAwbzc2dDZYUQ?oc=5","date":"2016-06-23","type":"pipeline","source":"BioPharma Dive","summary":"Selecta Biosciences raises $70 million in IPO, forges ahead with gout drug - BioPharma Dive","headline":"Selecta Biosciences raises $70 million in IPO, forges ahead with gout drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNOTl6U1BFbTFVYlF2ZGU5dmZtWmJ4dkhuRncwMFlFU3VGZTBVNDJrYlYwVTlVczlEUkVjWUl2aW1zOTJwWlExbGI4NEZTdFR4WTBod3N0Sk12ZUdDaEdiQUxwanlSWUhMUFhxRFRRTE16TlNGWUg1N1NuNFRDR2t4NVdkNEltbHQ0NmdjMDM3dS12SmhaQWtLLQ?oc=5","date":"2015-05-12","type":"pipeline","source":"Clinical Leader","summary":"Keeping Tabs On Gene Therapy? Big Pharma Is Closing In - Clinical Leader","headline":"Keeping Tabs On Gene Therapy? Big Pharma Is Closing In","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":1,"phase_2":2,"phase_1":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}